Dr Mariana Chavez MacGregor speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the latest updates in the field of hormone receptor positive HER2 negative breast cancer from this year's ASCO annual meeting.

She first highlights the DESTINY-Breast04 trial, which focuses on the use of trastuzumab deruxtecan in patients that are HER2 1 or 2 plus, believing that the results are practice changing.

Dr Chavez MacGregor also covers more studies from the metastatic setting including the MAINTAIN trial and also trials in the early stage setting.